France's Transgene 2025 net loss widens on higher financial costs

Transgene SA

24/03/2026 16:57

Overview

France biotech's full-year 2025 operating revenue rose to EUR 7.2 mln

Net loss widened to EUR 37.5 mln

Company raised EUR 105 mln and converted EUR 39 mln debt, funding operations until early 2028

Outlook

Company says it is funded until early 2028

Result Drivers

RESEARCH TAX CREDIT - Majority of operating revenue came from French research tax credit

CLINICAL TRIAL SPENDING - Operating expenses driven by R&D, mainly external costs for clinical projects, partly offset by partner re-invoicing

FOREIGN EXCHANGE LOSS - Financial loss increased due to negative foreign exchange effects from U.S. dollar depreciation

Company press release: ID:nGNE5xnBZd

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
EUR 7.2 mln
FY Net Income
-EUR 37.5 mln
FY Operating Expenses
EUR 42.3 mln
FY Operating Income
-EUR 35.1 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Transgene SA is €1.35, about 82.4% above its March 23 closing price of €0.74

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)